|
|
xiii | |
Abbreviations |
|
xv | |
|
A genomics approach to cytokine discovery |
|
|
1 | (19) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 | (1) |
|
cDNA-based methods for high-throughput gene discovery |
|
|
1 | (6) |
|
|
2 | (2) |
|
Selection method for candidate genes |
|
|
4 | (1) |
|
Case study of database analysis to identify a tissue-specific cytokine |
|
|
4 | (3) |
|
Identification of new chemokine family members |
|
|
7 | (2) |
|
MPIF-1, a chemokine with stem cell inhibitory activity |
|
|
7 | (2) |
|
Expansion of the TNF/TNF receptor repertoire |
|
|
9 | (4) |
|
Database approaches toward high-throughput discovery of novel cytokines |
|
|
13 | (7) |
|
|
16 | (4) |
|
Cytokine signal transduction |
|
|
20 | (29) |
|
|
|
|
|
|
20 | (1) |
|
Initiation of signal transduction by cytokine receptors |
|
|
20 | (2) |
|
|
20 | (1) |
|
Activation of receptor-associated tyrosine kinases |
|
|
21 | (1) |
|
Cytokine signalling pathways |
|
|
22 | (17) |
|
The Ras/mitogen activated protein kinase pathway |
|
|
24 | (5) |
|
The phosphoinositide-3-kinase pathway |
|
|
29 | (3) |
|
Pathways leading to gene activation |
|
|
32 | (5) |
|
Pathways leading to cell death |
|
|
37 | (2) |
|
Modulation of signal transduction pathways |
|
|
39 | (3) |
|
Negative regulation of kinase activation |
|
|
39 | (1) |
|
Negative regulation of the Ras/MAPK pathway |
|
|
39 | (2) |
|
Regulation of signal transduction by phosphatases |
|
|
41 | (1) |
|
|
42 | (7) |
|
|
43 | (6) |
|
|
49 | (22) |
|
|
|
|
|
|
|
|
|
|
49 | (1) |
|
Cloning cytokines and evaluating their functions |
|
|
49 | (1) |
|
Analysis of cytokine activity in vivo |
|
|
50 | (2) |
|
|
50 | (1) |
|
|
51 | (1) |
|
Regulation of cytokines in rheumatoid arthritis |
|
|
52 | (4) |
|
What are the upstream cytokine inducers of the cytokine network in RA? |
|
|
53 | (1) |
|
Cytokine interactions in animal models of arthritis |
|
|
54 | (1) |
|
What regulates the cytokine network? |
|
|
55 | (1) |
|
Immunoregulatory cytokines |
|
|
56 | (5) |
|
|
56 | (1) |
|
|
57 | (2) |
|
|
59 | (1) |
|
|
60 | (1) |
|
|
61 | (1) |
|
What maintains the cytokine network in rheumatoid arthritis? |
|
|
62 | (1) |
|
Demonstration of cytokine network interactions in vivo |
|
|
63 | (1) |
|
|
63 | (1) |
|
|
64 | (7) |
|
|
64 | (7) |
|
Cytokines and the Th1/Th2 paradigm |
|
|
71 | (32) |
|
|
|
|
|
Definitions of Th1 and Th2 cells |
|
|
71 | (2) |
|
Nature of Th1/Th2-polarizing signals |
|
|
73 | (6) |
|
Site of antigen presentation |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
74 | (1) |
|
Properties of the immunogen |
|
|
75 | (1) |
|
|
75 | (1) |
|
Peptide density and binding affinity |
|
|
75 | (1) |
|
|
76 | (2) |
|
|
78 | (1) |
|
Role of the genetic background in the Th1/Th2 development |
|
|
79 | (1) |
|
Intracellular signalling for Th1/Th2 development |
|
|
79 | (3) |
|
Intracellular signalling for Th2 development |
|
|
80 | (1) |
|
Intracellular signalling for Th1 development |
|
|
80 | (2) |
|
Cross-regulatory activity of Th1 and Th2 cytokines |
|
|
82 | (1) |
|
The Th1/Th2 paradigm in human diseases |
|
|
83 | (9) |
|
Transplantation rejection and tolerance |
|
|
83 | (1) |
|
Successful pregnancy and unexplained recurrent abortions |
|
|
84 | (1) |
|
|
84 | (2) |
|
|
86 | (3) |
|
Chronic inflammatory gastrointestinal disorders |
|
|
89 | (2) |
|
Progression of HIV infection |
|
|
91 | (1) |
|
|
92 | (11) |
|
|
93 | (10) |
|
|
103 | (23) |
|
|
|
|
|
|
|
|
|
|
103 | (1) |
|
|
104 | (1) |
|
Receptors and signal transduction |
|
|
105 | (2) |
|
|
107 | (1) |
|
Regulation of chemokine production |
|
|
107 | (1) |
|
Regulation of receptor expression during activation and deactivation of mononuclear phagocytes |
|
|
108 | (2) |
|
Regulation of receptor expression: dendritic cells |
|
|
110 | (1) |
|
|
111 | (15) |
|
Polarized Th1 and Th2 responses |
|
|
112 | (1) |
|
Tumours as a paradigm for the in vivo function of chemokines |
|
|
113 | (4) |
|
|
117 | (9) |
|
Cytokines and cytokine receptors encoded by viruses |
|
|
126 | (26) |
|
|
|
|
|
|
|
|
|
Role of cytokines in antiviral defence |
|
|
126 | (1) |
|
Pox viruses and herpesviruses |
|
|
126 | (1) |
|
Cytokines encoded by viruses |
|
|
127 | (7) |
|
|
129 | (1) |
|
|
130 | (2) |
|
|
132 | (1) |
|
|
132 | (2) |
|
|
134 | (1) |
|
Cytokine receptors encoded by viruses |
|
|
134 | (10) |
|
Soluble cytokine receptors |
|
|
134 | (9) |
|
|
143 | (1) |
|
Conclusions and future prospects |
|
|
144 | (8) |
|
|
145 | (7) |
|
Genetic variation in cytokines and relevance to inflammation and disease |
|
|
152 | (22) |
|
|
|
|
|
|
152 | (1) |
|
Cytokines as candidate genes |
|
|
153 | (2) |
|
TNF locus polymorphisms and the MHC |
|
|
155 | (3) |
|
TNF locus polymorphism and diseases |
|
|
156 | (2) |
|
The interleukin 1 gene cluster |
|
|
158 | (2) |
|
IL-1 locus polymorphisms and diseases |
|
|
159 | (1) |
|
Susceptibility or severity? |
|
|
160 | (1) |
|
IL-4 and IL-4R polymorphisms and diseases |
|
|
160 | (1) |
|
IL-6 gene polymorphism and diseases |
|
|
161 | (1) |
|
Il-10 gene polymorphism and diseases |
|
|
162 | (1) |
|
Chemokine receptor gene polymorphisms |
|
|
162 | (1) |
|
|
163 | (11) |
|
|
164 | (10) |
|
Therapeutic manipulation of the cytokine network |
|
|
174 | (11) |
|
|
|
|
|
|
174 | (1) |
|
Recombinant cytokine therapy of cancer |
|
|
174 | (5) |
|
IFN-α therapy of malignant disease |
|
|
175 | (1) |
|
IFN-γ therapy of malignant disease |
|
|
176 | (1) |
|
TNF-α therapy of malignant disease |
|
|
177 | (1) |
|
IL-12 therapy of malignant disease |
|
|
178 | (1) |
|
The potential of cytokine antagonist therapy in cancer |
|
|
179 | (2) |
|
Inflammatory cytokines and cancer --- the case for cytokine antagonist therapy |
|
|
180 | (1) |
|
Other cytokine signalling targets |
|
|
181 | (1) |
|
Mechanisms of action of cytokine therapy in malignancy |
|
|
181 | (1) |
|
|
182 | (2) |
|
|
182 | (2) |
|
The important of understanding the tumour cytokine network |
|
|
184 | (1) |
|
Sequential or combination biological therapy |
|
|
184 | (1) |
|
|
184 | (1) |
References |
|
185 | (6) |
Index |
|
191 | |